Quick Answer
ANAPTYSBIO, INC reported Cash And Cash Equivalents At Carrying Value of $238.20 million for the year ending 2025.
- ANAPTYSBIO, INC showed an increase of +93.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ANAPTYSBIO, INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $96.75 million | Q2 2017: $30.75 million | Q3 2017: $26.67 million | Q1 2018: $69.47 million | Q2 2018: $57.06 million | Q3 2018: $293.41 million | Q1 2019: $105.85 million | Q2 2019: $146.55 million | Q3 2019: $182.90 million | Q1 2020: $165.32 million | Q2 2020: $221.17 million | Q3 2020: $209.15 million | Q1 2021: $284.15 million | Q2 2021: $332.25 million | Q3 2021: $336.33 million | Q1 2022: $166.41 million | Q2 2022: $71.70 million | Q3 2022: $58.55 million | Q1 2023: $94.56 million | Q2 2023: $35.21 million | Q3 2023: $26.30 million | Q1 2024: $53.70 million | Q2 2024: $71.82 million | Q3 2024: $191.58 million | Q1 2025: $98.64 million | Q2 2025: $44.30 million | Q3 2025: $109.83 million.
- Over the full 10 years of available data (2016 to 2025), ANAPTYSBIO, INC's Cash And Cash Equivalents At Carrying Value has grown by 364.9%.
- Historical annual values: Fiscal year 2025: $238.20 million | Fiscal year 2024: $123.08 million | Fiscal year 2023: $35.97 million | Fiscal year 2022: $71.31 million | Fiscal year 2021: $495.73 million | Fiscal year 2020: $250.46 million | Fiscal year 2019: $171.02 million | Fiscal year 2018: $113.60 million | Fiscal year 2017: $81.19 million | Fiscal year 2016: $51.23 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: